Key insights
- Leerink Partners upgraded JNJ to "Outperform" with a $265 price target, citing strong revenue growth driven by new drug launches and expansion in oncology and immunology. The firm projects a 7.2% revenue CAGR between 2026 and 2031, exceeding consensus. This positive outlook could boost investor confidence in JNJ and the broader healthcare sector.
Investing.com -- Analysts at Leerink Partners upgraded Johnson & Johnson from “Market Perform” to “Outperform,” citing accelerating growth prospects driven by a wave of new drug launches and expanding oncology and immunology franchises. The brokerage also raised its 12-month price target to $265 from $252, implying roughly 18% upside from the stock’s recent close.
Leerink said the pharmaceutical giant is entering a period of stronger revenue expansion led by four key products: Icotyde, Inlexzo, Rybrevant, and Tremfya. The firm now forecasts Johnson & Johnson’s revenue compound annual growth rate at 7.2% between 2026 and 2031, above Wall Street consensus expectations of about 6%.